Back to Hematology
Hematologyv2020Evidence-Based

VTE-BLEED Score

Assesses bleeding risk on anticoagulation therapy in patients with venous thromboembolism (VTE). This validated risk score enables better stratification of bleeding risk during stable anticoagulation after a first VTE episode. Unlike bleeding risk scores derived from atrial fibrillation patients, the VTE-BLEED score is specifically designed for VTE patients who have different comorbidity profiles and risk factors.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
vte bleed score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The VTE-BLEED Score is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Age ≥60 years (1.5 points) + Active cancer (2 points) + Male with uncontrolled hypertension (1 point) + Anemia (1.5 points) + History of bleeding (1.5 points) + Renal dysfunction (1.5 points). Score <2 = Low risk, Score ≥2 = Elevated risk.

Clinical Pearls & Practice Notes

  • Designed for patients on stable anticoagulation after 30 days of treatment for DVT or PE
  • Most validated bleeding risk score in VTE settings with good prediction power for major bleeding
  • Validated for various direct oral anticoagulants (DOACs) and vitamin K antagonists
  • Can identify patients at risk of intracranial and fatal bleeding events
  • VTE patients typically have different comorbidity profile than atrial fibrillation patients
  • Score should not be used as definitive exclusion from anticoagulation therapy
  • Consider individual patient factors and clinical judgment in treatment decisions
  • Active cancer definition includes currently receiving treatment, treated within 6 months, or metastatic disease
  • Uncontrolled hypertension applies only to male patients in this score
  • Anemia thresholds: <13 g/dL in men, <12 g/dL in women
  • Renal dysfunction specifically refers to creatinine clearance 30-60 mL/min range
  • Score developed and validated in European VTE cohorts

Evidence & Literature Citations

  1. Klok FA, Hösel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J. 2016;48(5):1369-1376. doi: 10.1183/13993003.00280-2016
  2. Barco S, Klok FA, Mahé I, et al. Impact of sex, age, and risk factors for venous thromboembolism on the risk of major bleeding in patients with acute venous thromboembolism. Circulation. 2020;141(1):8-17. doi: 10.1161/CIRCULATIONAHA.119.042716
  3. Mahé I, Chidiac J, Bertoletti L, et al. The clinical course of venous thromboembolism may differ according to cancer site. Am J Med. 2017;130(3):337-347. doi: 10.1016/j.amjmed.2016.10.017
  4. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. Haematologica. 2007;92(2):199-205. doi: 10.3324/haematol.10516

Score Interpretation Ranges

Low Risk0 – 1.9 pts

Low bleeding risk on anticoagulation

Elevated Risk2 – 10 pts

Elevated bleeding risk on anticoagulation

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.